Short answer
ANAPTYSBIO, INC (ANAB) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $76M (up 154.3% year over year) with net income of $15M.
Q3 2025 key financials · XBRL
- Revenue
- $76M
- +154.3% YoY · +242.8% QoQ
- Net income
- $15M
- +146.0% YoY · +139.1% QoQ
- Operating margin
- 45.5%
- EPS (diluted)
- $0.46
- +141.4% YoY · +134.3% QoQ
Source: XBRL data from the ANAPTYSBIO, INC (ANAB) Q3 2025 10-Q on SEC EDGAR. USD.
ANAPTYSBIO, INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk from June 2024 U.S. Supreme Court decision reversing Chevron doctrine, increasing uncertainty in FDA regulatory reviews
- Most materially updated risk: ongoing Phase 2 trials of rosnilimab may show differing efficacy or safety, impacting development timelines and success
- Impactful legal risk: heightened False Claims Act litigation risks with potential fines exceeding $1.0 billion for off-label promotion and related compliance burdens
- Operational risk: challenges in patient enrollment for clinical trials due to eligibility criteria, competing treatments, and trial site availability affect near-term development progress
- Financial risk: reliance on additional capital raises with uncertain availability may impede ability to complete development and commercialization of product candidates
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ANAPTYSBIO, INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.